1. Home
  2. API vs NNNN Comparison

API vs NNNN Comparison

Compare API & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agora Inc.

API

Agora Inc.

HOLD

Current Price

$4.39

Market Cap

339.0M

Sector

Technology

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$5.58

Market Cap

340.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
API
NNNN
Founded
2013
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
339.0M
340.2M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
API
NNNN
Price
$4.39
$5.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
123.4K
252.4K
Earning Date
05-26-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.46
N/A
Revenue Next Year
$12.87
N/A
P/E Ratio
$92.30
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$3.14
$5.13
52 Week High
$5.50
$51.33

Technical Indicators

Market Signals
Indicator
API
NNNN
Relative Strength Index (RSI) 56.72 29.08
Support Level $3.96 N/A
Resistance Level $4.31 $12.10
Average True Range (ATR) 0.12 0.48
MACD 0.02 0.05
Stochastic Oscillator 79.41 23.43

Price Performance

Historical Comparison
API
NNNN

About API Agora Inc.

Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: